Aryzta AG (ARZTF)

Aryzta AG (ARZTF) — VMCI valuation read

Headline read on ARZTF: VMCI of 53/100 versus a Consumer Defensive sector median of 50. The 3-point above-median position is what makes Aryzta AG a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on ARZTF: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on ARZTF: value (ARZTF trades at 27.0x earnings, 50% above the Consumer Defensive median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Consumer Defensive median (10.0%)), and risk (net debt to EBITDA of 1.4x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Consumer Defensive 12.0x baseline.

ARZTF fell 1.1% over the trailing 7 days, with a +7.6% read on a 30-day basis.